登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07531979,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically confirmed locally advanced or metastatic esophageal squamous cell carcinoma.
入选标准第 4 条
No prior systemic therapy for ESCC. Patients who have received neoadjuvant or adjuvant therapy must have experienced disease progression or recurrence more than 6 months after completion of that treatment.
入选标准第 5 条
Patients with metastatic disease must have at least one measurable lesion per RECIST 1.1 criteria; patients with disease after neoadjuvant therapy must have an evaluable lesion.
入选标准第 6 条
Prior treatment with any anti-EGFR monoclonal antibody, or with anti-PD-1/PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, CTLA-4 antibody, or any other drug/antibody targeting T-cell co-stimulation or checkpoint pathways.
排除标准第 1 条
ECOG performance status of 0 or 1, with no deterioration within 7 days.
入选标准第 3 条
Hemoglobin (HGB) ≥ 90 g/L.
入选标准第 8 条
Absolute neutrophil count (NEUT) ≥ 1.5 × 10⁹/L.
入选标准第 9 条
Platelet count (PLT) ≥ 80 × 10⁹/L.
入选标准第 10 条
Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN).
入选标准第 11 条
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN.
入选标准第 12 条
Creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula).
入选标准第 13 条
Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.
入选标准第 17 条
Male or non-pregnant, non-lactating female.
入选标准第 2 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07531979,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥ 18 years. Male or non-pregnant, non-lactating female. ECOG performance status of 0 or 1, with no deterioration within 7 days. Histologically confirmed locally advanced or metastatic esophageal squamous cell carcinoma. No prior systemic therapy for ESCC. Patients who have received neoadjuvant or adjuvant therapy must have experienced disease progression or recurrence more than 6 months after completion of that treatment. Patients with metastatic disease must have at least one measurable lesion per RECIST 1.1 criteria; patients with disease after neoadjuvant therapy must have an evaluable lesion. Adequate organ and bone marrow function, as demonstrated by the following laboratory values: Hemoglobin (HGB) ≥ 90 g/L. Absolute neutrophil count (NEUT) ≥ 1.5 × 10⁹/L. Platelet count (PLT) ≥ 80 × 10⁹/L. Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN. Creatinine clearance ≥ 50 mL/min (calculated by the Cockcroft-Gault formula). Urine protein < (++) or 24-hour urinary protein < 1.0 g. Normal coagulation function and no active bleeding: International Normalized Ratio (INR) ≤ 1.5. Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN. For women of childbearing potential: negative pregnancy test (serum or urine) within 14 days prior to enrollment, and agreement to use adequate contraception during the study period and for 8 weeks after the last dose of study drug. For men: surgically sterile or agreement to use adequate contraception during the study period and for 8 weeks after the last dose of study drug. Expected survival ≥ 6 months. Patient voluntarily participates in the study and signs the informed consent form (ICF). Patient is expected to be compliant and able to undergo follow-up for efficacy and adverse events as required by the protocol.排除标准:Exclusion Criteria:
Prior treatment with any anti-EGFR monoclonal antibody, or with anti-PD-1/PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, CTLA-4 antibody, or any other drug/antibody targeting T-cell co-stimulation or checkpoint pathways. Administration of a live vaccine within 4 weeks prior to enrollment or anticipated during the study period. Active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment. Prior allogeneic bone marrow transplantation or solid organ transplant. Uncontrolled hypertension at enrollment, defined as: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg. Any disease or condition affecting drug absorption at enrollment. Clinically significant cardiovascular disease, including but not limited to: acute myocardial infarction within 6 months prior to enrollment; severe/unstable angina or coronary artery bypass grafting; congestive heart failure > New York Heart Association (NYHA) Class 2; ventricular arrhythmias requiring medication; left ventricular ejection fraction (LVEF) < 50%. Active or uncontrolled severe infection (≥ CTCAE v5.0 Grade 2 infection). Known HIV infection. Known clinically significant liver disease, including viral hepatitis [known hepatitis B virus (HBV) carriers must be excluded if they have active HBV infection, i.e., HBV DNA positive (>1×10⁴ copies/mL or >2000 IU/mL); known hepatitis C virus (HCV) infection with HCV RNA positive (>1×10³ copies/mL)]. Any other disease, clinically significant metabolic abnormality, physical examination finding, or laboratory abnormality that, in the investigator's judgment, reasonably suggests the presence of a disease or condition that contraindicates the use of the investigational drug (e.g., a condition associated with seizures requiring treatment), would affect the interpretation of study results, or would place the patient at high risk. Patients deemed by the investigator to be unsuitable for participation in this study.
引自 ClinicalTrials.gov, NCT07531979, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07531979,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。